Lilly’s Donanemab, Now At FDA, Poised To Join Alzheimer’s Armamentarium

 
• By Jessica Merrill
  
Fighter Jets
Lilly believes donanemab is well positioned to join the Alzheimer's fight • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D